Ocular manifestations in psoriasis of Iraqi patients
DOI:
https://doi.org/10.66344/jpad.v34i2.2694Keywords:
Ocular, Psoriasis, HLAAbstract
Objective This was a cross-sectional study established in Iraq Dhi Qar Governorate, which aimed to determine the prevalence of ocular manifestations in psoriasis among Iraqi patients.
Methods This study was designed according to the frequency of ocular manifestations in psoriasis in Iraq, where reliance was placed on the statistical analysis program SPSS and the Schirmer test. To do a semiquantitative test of tear production that measures the physical tendency of a fluid to travel along a strip of porous material by capillary action due to surface tension, for the diagnosis of dry eye. The statistical analysis program SPSS was relied on to analyse demographic data and information about patients.
Results/Conclusion The mean age of the patients was 45.2±13.5, and results found a statistical correlation between ocular diseases and psoriasis in patients. In addition, other abnormalities in the eye were found, including keratitis and blepharitis. Moreover, the presence of eye diseases affects the degree of disease activity and the cutaneous form of psoriasis. It can affect one or both eyes, as it generally appears with outbreaks of infections that recur over time. About half of uveitis is due to an unknown cause.
References
1. Balato N., Napolitano M., Ayala F., Patruno C., Megna M., Tarantino G. Nonalcoholic fatty liver disease, spleen, and psoriasis: New aspects of low-grade chronic inflammation. World J Gastroenterol. 2015; 21:6892–7. doi: 10.3748/wjg. v21.i22.6892. [PMC free article]
2. Ruggiero A., Fabbrocini G., Cinelli E., Megna M. Efficacy and safety of guselkumab in psoriasis patients who failed usteki-numab and/or anti-interleukin-17 treatment: A real-life 52-week retrospective study. Dermatol Ther. 2020;13:4673. [PubMed] [Google Scholar]
3. Oliveira M.d.F., Rocha B.d.O., Duarte G.V. Psoriasis: Classical and emerging comorbidities. An Bras Dermatol. 2015; 90:9–20. doi: 10.1590/abd1806-4841.20153038. [PMC free article]
4. Demerdjieva Z., Mazhdrakova I., Tsankov N. Ocular changes in patients with psoriasis. Clin Dermatol. 2019;37:663–667. doi: 10.1016/j.clindermatol.2019.07.029.
5. Chimenti M.S., Triggianese P., Salandri G., Conigliaro P., Canofari C., Caso F., Costa L., Nucci C., Aiello F., Cesareo M., et al. A Multimodal Eye Assessment in Psoriatic Arthritis Patients Sine-Psoriasis: Evidence for a Potential Association with Systemic Inflammation. J Clin Med. 2020;9:719. doi: 10.3390/jcm9030719. [PMC free article]
6. Lam M., Steen J., Lu J.D., Vender R. The Incidence and Prevalence of Uveitis in Psoriasis: A Systematic Review and Me-ta-Analysis. J Cutan Med Surg. 2020;24:601–7. doi: 10.1177/1203475420952420.
7. Murray P.I., Rauz S. The eye and inflammatory rheumatic diseases: The eye and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis. Best Pr Res Clin Rheumatol. 2016;30:802–25. doi: 10.1016/j.berh.2016.10.007.
8. Abbouda A., Abicca I., Fabiani C., Scappatura N., García P.P., Scrivo R., Priori R., Paroli M.P. Psoriasis and Psoriatic Ar-thritis-Related Uveitis: Different Ophthalmological Manifestations and Ocular Inflammation Features. Semin Ophthalmol. 2017;32:715–20. doi: 10.3109/08820538.2016.1170161.
9. Van de Kerkhof P.C., Murphy G.M., Austad J., Ljungberg A., Cambazard F., Duvold L.B. Psoriasis of the face and flexures. J Dermatol Treat. 2007;18:351–60. doi: 10.1080/09546630701341949.
10. Ghalamkarpour F., Baradaran-Rafii A., Sadoughi M.M., Abdollahimajd F., Younespour S., Zargari O., Rudolph R.I. Ocular findings in patients with psoriasis: Is it related to the side effects of treatment or to psoriasis itself? A case-control study. J Dermatol Treat. 2019;31:27–32. doi: 10.1080/09546634.2019.1577947.
11. Kilic B., Dogan U., Parlak A.H., Goksugur N., Polat M., Serin D., Ozmen S. Ocular findings in patients with psoriasis. Int J Dermatol. 2013;52:554–9. doi: 10.1111/j.1365-4632.2011.05424. x.
12. Rehal B., Modjtahedi B.S., Morse L.S., Schwab I.R., Maibach H.I. Ocular psoriasis. J Am Acad Dermatol. 2011;65:1202–12. doi: 10.1016/j.jaad.2010.10.032.
13. Balato A., Di Costanzo L., Patruno C., Ayala F., Megna M., Balato N. Psoriasis or “psoriases”? G Ital Dermatol Venereol. 2013;148:649–50. [PubMed] [Google Scholar]
14. Bernhard J.D., Kumar B., Sharma V.K. Is Eyelid Involvement a Sign of Severe Psoriasis? /Papulonecrotic Tuberculides on Glans penis? Dermatology. 1987;174:151–2. doi: 10.1159/000249009.
15. Cruz N.F.S.D., Brandão L.S., Cruz S.F.S.D., Cruz S.A.S.D., Pires C.A.A., Carneiro F.R.O. Ocular manifestations of psoriasis. Arq Bras Oftalmol. 2018;81:219–25. doi: 10.5935/0004-2749.20180044.
16. Aragona E., Rania L., Postorino E.I., Interdonato A., Giuffrida R., Cannavò S.P., Puzzolo D., Aragona P. Tear film and ocular surface assessment in psoriasis. Br J Ophthalmol. 2017;102:302–8. doi: 10.1136/bjophthalmol-2017-310307.
17. Vadalà M., Davì C., Strano G.I., Giuffrida E., Scrivo B., Ventura N., Castellucci M., Cillino S., Cammà C., Cappello M. The ocular manifestations in IBD screening (OMIS) questionnaire: Pilot study on detection of ocular involvement in inflammatory bowel diseases. Int Ophthalmol. 2020;40:2569–76. doi: 10.1007/s10792-020-01437-x.
18. Rendon A., Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019;20:1475. doi: 10.3390/ijms20061475. [PMC free article]
19. Megna M., Fabbrocini G., Cinelli E., Camela E., Ruggiero A. Guselkumab in moderate to severe psoriasis in routine clinical care: An Italian 44-week real-life experience. J Dermatol Treat. 2020:1–5. Doi 10.1080/09546634.2020.1800577.
20. Megna M., Fabbrocini G., Ruggiero A., Cinelli E. Efficacy and safety of risankizumab in psoriasis patients who failed an-ti-IL-17, anti-12/23 and/or anti-IL-23: Preliminary data of a real-life 16-week retrospective study. Dermatol Ther. 2020; 33:4144. doi: 10.1111/dth.14144.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Ahmed Abdulhussein Kawen, Muataz Hasan Jaaz
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
